Endocyte, Inc. (ECYT) Sets 1-Year High on May, 16 at $12.56

May 16, 2018 - By Joseph Norton

Big Money Sentiment increased to 1.36 in Q4 2017. It has change of 1.04, from 2017Q3’s 0.32. The ratio increased due to Endocyte, Inc. positioning: 11 sold and 14 reduced. 19 funds amassed positions and 15 increased positions. Investors holded 8.27 million in 2017Q3 but now own 19.91 million shares or 140.76% more.
Financial Bank Of Mellon Corporation reported 0% in Endocyte, Inc. (NASDAQ:ECYT). Leisure Cap Mgmt has invested 0.1% in Endocyte, Inc. (NASDAQ:ECYT). Barclays Public Limited owns 103,109 shs or 0% of their US capital. Morgan Stanley has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Renaissance Ltd Liability Corp reported 293,580 shs stake. The Ontario – Canada-based Royal Bankshares Of Canada has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Baker Bros Advisors L P owns 1.09M shs or 0.04% of their US capital. Bancorp Of America De has invested 0% in Endocyte, Inc. (NASDAQ:ECYT). Bb&T Securities Ltd Liability Corp, a Virginia-based fund reported 20,750 shs. Susquehanna Intl Group Inc Llp reported 17,949 shs stake. Tower Ltd Llc (Trc) holds 0% in Endocyte, Inc. (NASDAQ:ECYT) or 910 shs. D E Shaw & Comm Incorporated, New York-based fund reported 2.08M shs. Northern Trust Corp holds 0% or 80,856 shs in its capital. Fmr Ltd Com reported 2.10M shs. Ra Capital Management Limited Liability Corporation reported 3.36M shs stake.

Endocyte, Inc. had 1 sale and 0 insider purchases since March 9, 2018. This’s net activity of $45,677.

Today 1-year high was reached by Endocyte, Inc. (NASDAQ:ECYT) with $13.44 target or 7.00 % above today’s $12.56 price per share. It was announced on May, 16 by Barchart.com. The company has $866.25M MC. $60.64M more could be NASDAQ:ECYT valuation at $13.44 share price.

Ticker’s shares touched $12.56 during the last trading session after 3.72% change.Endocyte, Inc. has volume of 2.13 million shares. Since May 16, 2017 ECYT has risen 296.90% and is uptrending. ECYT outperformed the S&P500 by 285.35%.

Endocyte, Inc. (NASDAQ:ECYT) is expected to publish earnings on August, 14., as reported by RTT. Analysts predict $-0.19 EPS, which is $0.09 up or 32.14 % from 2017’s $-0.28 EPS. Last quarter $-0.16 EPS was reported. Analysts forecasts 18.75 % negative EPS growth this quarter.

Endocyte, Inc. (NASDAQ:ECYT) Ratings Coverage

A total of 3 analysts rate Endocyte (NASDAQ:ECYT) as follows: 3 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. The firm has $20 highest and $17 lowest target. The avg target $18.50 is 47.29% above the last ($12.56) price. (NASDAQ:ECYT) has 3 ratings reports on May 16, 2018 according to StockzIntelligence. On Tuesday, February 27 Cowen & Co upgraded the shares of ECYT in report to “Outperform” rating.

A couple more Endocyte, Inc. (NASDAQ:ECYT) news were released by: Globenewswire.com which released on May 02, 2018 “Endocyte Announces First Quarter 2018 Earnings Call”, also Globenewswire.com on May 09, 2018 released “Endocyte Provides First Quarter 2018 Financial Results and Operational Update”, the next Nasdaq.com is “New Research: Key Drivers of Growth for OFG, Oshkosh, Vishay Precision Group, Endocyte, BioCryst Pharmaceuticals …” on April 26, 2018. Seekingalpha.com has article titled “Endocyte’s (ECYT) CEO Mike Sherman on Q1 2018 Results – Earnings Call Transcript”.

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States.The firm is worth $866.25 million. The firm uses its technology to create novel small molecule drug conjugates and companion imaging agents.Currently it has negative earnings. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer.

Endocyte, Inc. (NASDAQ:ECYT) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.